Our top pick for
Simulations Plus Inc is a health information services business based in the US. Simulations Plus shares (SLP) are listed on the NASDAQ and all prices are listed in US Dollars. Simulations Plus employs 129 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$37.89|
|52-week range||$36.90 - $90.72|
|50-day moving average||$41.63|
|200-day moving average||$50.61|
|Wall St. target price||$64.67|
|Dividend yield||$0.24 (0.59%)|
|Earnings per share (TTM)||$0.57|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-4.92%|
|1 month (2021-09-23)||-3.78%|
|3 months (2021-07-23)||-19.98%|
|6 months (2021-04-23)||-45.06%|
|1 year (2020-10-22)||-45.88%|
|2 years (2019-10-22)||11.87%|
|3 years (2018-10-22)||84.38%|
|5 years (2016-10-21)||334.77%|
Valuing Simulations Plus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Simulations Plus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Simulations Plus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 70x. In other words, Simulations Plus shares trade at around 70x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Simulations Plus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.0774. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Simulations Plus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Simulations Plus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $16.6 million.
The EBITDA is a measure of a Simulations Plus's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$46.2 million|
|Operating margin TTM||31.84%|
|Gross profit TTM||$30.9 million|
|Return on assets TTM||7.63%|
|Return on equity TTM||11.01%|
|Market capitalisation||$802.3 million|
TTM: trailing 12 months
There are currently 2.0 million Simulations Plus shares held short by investors – that's known as Simulations Plus's "short interest". This figure is 1.5% down from 2.1 million last month.
There are a few different ways that this level of interest in shorting Simulations Plus shares can be evaluated.
Simulations Plus's "short interest ratio" (SIR) is the quantity of Simulations Plus shares currently shorted divided by the average quantity of Simulations Plus shares traded daily (recently around 132647.4233529). Simulations Plus's SIR currently stands at 15.33. In other words for every 100,000 Simulations Plus shares traded daily on the market, roughly 15330 shares are currently held short.
However Simulations Plus's short interest can also be evaluated against the total number of Simulations Plus shares, or, against the total number of tradable Simulations Plus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Simulations Plus's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Simulations Plus shares in existence, roughly 100 shares are currently held short) or 0.1299% of the tradable shares (for every 100,000 tradable Simulations Plus shares, roughly 130 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Simulations Plus.
Find out more about how you can short Simulations Plus stock.
Dividend payout ratio: 53.33% of net profits
Recently Simulations Plus has paid out, on average, around 53.33% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.6% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Simulations Plus shareholders could enjoy a 0.6% return on their shares, in the form of dividend payments. In Simulations Plus's case, that would currently equate to about $0.24 per share.
Simulations Plus's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Simulations Plus's most recent dividend payout was on 1 August 2021. The latest dividend was paid out to all shareholders who bought their shares by 21 October 2021 (the "ex-dividend date").
Simulations Plus's shares were split on a 2:1 basis on 1 October 2007. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Simulations Plus shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Simulations Plus shares which in turn could have impacted Simulations Plus's share price.
Over the last 12 months, Simulations Plus's shares have ranged in value from as little as $36.9 up to $90.7237. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Simulations Plus's is -0.0317. This would suggest that Simulations Plus's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Simulations Plus has bucked the trend.
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.